Indometacin - Iroko Pharmaceuticals

Drug Profile

Indometacin - Iroko Pharmaceuticals

Alternative Names: Indomethacin; Indomethacin nano-formulation - Iroko Pharmaceuticals; IP-940; Lower-dose submicron indomethacin - Iroko Pharmaceuticals; Submicron indomethacin - Iroko Pharmaceuticals; Tiforbex; Tivorbex

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator iCeutica
  • Developer Iroko Pharmaceuticals
  • Class Analgesics; Antirheumatics; Chlorobenzenes; Indoles; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute pain
  • Phase II Postoperative pain

Most Recent Events

  • 01 Jan 2017 Iroko Pharmaceuticals completes a phase IIa trial in Postoperative pain (In children, In adolescents) in USA (PO) (NCT02633969)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Dec 2015 Phase-II clinical trials in Postoperative pain (In children, In adolescents) in USA (PO) (NCT02633969)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top